O'Flaherty, E <br/><br/>
Viability and quantification of progenitor cells in venesected blood from patients receiving escalated-dose epirubicin and cyclophosphamide with G-CSF for lymphoma: potential role in further increasing dose-intensity.  [electronic resource] 

 -  Leukemia & lymphoma  Oct 1997 
 - 343-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1042-8194 
<br/><br/><label>Standard No.: </label>10.3109/10428199709059689  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Blood Preservation<br/>Cell Count<br/>Cell Survival--drug effects<br/>Cells, Cultured<br/>Cryopreservation<br/>Cyclophosphamide--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Epirubicin--administration & dosage<br/>Erythroid Precursor Cells--drug effects<br/>Granulocyte Colony-Stimulating Factor--administration & dosage<br/>Hematopoietic Stem Cells--drug effects<br/>Humans<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Phlebotomy